Every drug hunting project needs its own IP strategy but the current purely market-driven approaches to drug discovery and development alone are insufficient to drive equitable access to new therapies either in preparation for, or in response to, pandemics. Following the experiences gained from the COVID Moonshot program and the ASAP AViDD drug discovery
Summary of the ACSMEDI-EFMC Medicinal Chemistry Frontiers in May 2025 In May, we had a great time exhibiting at the ACSMEDI-EFMC Medicinal Chemistry Frontiers in Chicago. We enjoyed catching up with clients to discuss how our medicinal chemistry consultants can lead/advise on projects and how our MCPairs software can help chemists choose which compounds to
Summary of 8th RSC-BMCS / SCI Symposium on Ion Channels as Therapeutic Targets – April 2025 March 31st – 1st April 2025 Hinxton Hall, Wellcome Genome Campus, Cambridge By Dr Al Dossetter The SCI/RSC Ion-channels conference covers all aspects of ion-channel research; thus there is a mix of medicinal chemistry / drug discovery, protein bio-science
Summary of BMCS 2nd Conformational Design in Drug Discovery Conference 2025 Monday 3rd March 2025 The Discovery Centre – AstraZeneca, Cambridge, UK By Dr Al Dossetter Earlier this week, we had the pleasure of attending the 2nd Conformational Design conference held at The Discovery Centre, AZ; this also afforded us the opportunity to have a
Figure 1: The Structure of zoliflodacin Introduction Zoliflodacin (Figure 1, above) is an orally administered DNA gyrase (topoisomerase) inhibitor, under study for the treatment of Gonorrhoea. The Global Antibiotics Research and Development Partnership (GARDP) recently announced that the primary endpoint for its phase 3 clinical trial (noninferiority to ceftriaxone/azithromycin) was met.1,2 In isolation,
MCPairs v1.9 release is automatically available to all users: MCPairs version 1.9 went live last weekend. All Online users are upgraded to the new platform, and all new tools are available to everyone. On logging on you will notice the change in the layout of the dashboard as CoreDesign® has been added. This joins RuleDesign®
Recent bRo5 publications Figure 1: Picture summarising the limitations of obeying the Ro5 and the versatility obtained by going beyond (www.sciencedirect.com/science/article/abs/pii/S1367593117300480?via%3Dihub). Cast our minds back... It’s been more than 25 years since a Pfizer chemist: Christopher Lipinski, published1 his influential analysis of the calculated physical properties of a set of candidate drugs, leading to the well-known
Available Immediately - Direct SARkush We have added a lightweight GUI interface to MCPairs Online, that is immediately available to all users. This front end is similar to MyPairs and the input files are the same type. For comp.chem. the mcpcli route is still available, but this method provides is useful for those who are
From PhD to Drug Hunter By Dr Jess Stacey When I first arrived at MedChemica, I was given the task to create a new tool that makes small changes to a molecule's core, whilst ensuring suggestions are realistic and synthetically tractable. This scaffold hoping tool become known as CoreDesign®, see Figure 1. At the time
Not Burning Enough Calories: An odd thing has happened, well not that odd really. I wrote recently about the joy of Green Commuting. Last month we moved office to the centre of Macclesfield, which is so much closer to where I live. So what is odd? It mush be easier to Green commute now –
© 2025 Medchemica | All rights reserved | Designed & Built by Greenlight Web